更新于:2026-02-26

Chikungunya virus vaccine (Valneva)

概要

基本信息

药物类型
减毒活疫苗、预防性疫苗
别名
Chikungunya Vaccine, Live、Live-attenuated CHIKV、VLA 1553
+ [2]
靶点-
作用方式
刺激剂
作用机制
免疫刺激剂
治疗领域
在研适应症
非在研适应症-
原研机构
非在研机构-
最高研发阶段批准上市
首次获批日期
美国 (2023-11-09),
最高研发阶段(中国)-
特殊审评快速通道 (美国)、加速批准 (美国)、优先药物(PRIME) (欧盟)、加速审评 (欧盟)、优先审评 (美国)、突破性疗法 (美国)
登录后查看时间轴

研发状态

10 条最早获批的记录,
登录
后查看更多信息
适应症国家/地区公司日期
基孔肯雅热
美国
2023-11-09
登录后查看更多信息

临床结果

适应症
分期
评价
查看全部结果
研究
分期
人群特征评价人数分组结果评价发布日期
临床2期
304
鬱艱襯衊衊壓膚網憲繭(襯鏇築夢鹹製醖鹹築選) = too infrequent for meaningful comparisons 蓋範網夢積鏇獵蓋積齋 (淵獵鬱鏇衊夢衊鏇積顧 )
积极
2026-02-06
临床3期
754
IXCHIQ® Chikungunya Vaccine
糧構遞鹹夢願齋淵鹽艱(範鬱艱艱願顧遞鑰鏇廠) = 構蓋壓憲築繭積願夢膚 繭遞衊鬱築夢鬱築艱鬱 (製廠醖淵鏇積餘遞鏇獵 )
积极
2025-01-20
临床3期
278
獵獵夢廠襯窪構廠憲鬱(範窪鏇廠鹽醖襯願餘壓) = 齋鑰願憲廠鹽顧壓蓋願 齋淵顧襯鏇衊壓觸鹽觸 (醖夢糧構窪鑰餘膚醖醖 )
积极
2024-12-03
临床3期
754
live-attenuated chikungunya virus vaccine
(VLA1553)
鏇壓遞鹹構鏇廠衊顧繭(餘積簾鑰顧簾淵糧窪製) = Most (365 [93%] of 393) adverse events were of mild or moderate intensity, VLA1553 was generally well tolerated. When compared with placebo, participants exposed to VLA1553 had a significantly higher frequency of related adverse events (351 [69.9%] of 502 vs 121 [48.0%] of 252; p<0.0001), mostly headache, myalgia, fatigue, and fever. Among four reported serious adverse events (three in the VLA1553 group and one in the placebo group), one was classified as possibly related to VLA1553: a high-grade fever. Among 20 adverse events of special interest (ie, symptoms suggesting chikungunya-like disease), 16 were classified as related to trial vaccination (15 in the VLA1553 group and one in the placebo group), with severe symptoms reported in four participants (fever, headache, or arthralgia). 17 adverse events of special interest resolved within 1 week. Among 85 participants with arthralgia (68 in the VLA1553 group and 17 in the placebo group), eight adolescents had short-lived (range 1-5 days), mostly mild recurring episodes (seven in the VLA1553 group and one in the placebo group). The median duration of arthralgia was 1 day (range 1-5 days). The frequency of injection site adverse events for VLA1553 was higher than in the placebo group (161 [32%] vs 62 [25%]), but rarely severe (two [<1%] in the VLA1553 group and one [<1%] in the placebo group). After administration of VLA1553, there was a significantly lower frequency of solicited adverse events in participants who were seropositive at baseline compared with those who were seronegative (53% vs 74%; p<0.0001) including headache, fatigue, fever, and arthralgia. 醖襯選艱繭鑰鹹衊糧顧 (願蓋簾範淵積選艱繭範 )
积极
2024-09-01
live-attenuated chikungunya virus vaccine
(Placebo)
临床3期
234
鑰醖鹽廠壓餘範鑰構築(鏇獵壓壓簾願願壓鏇淵) = 艱鑰製獵糧網獵遞構製 鏇憲醖鑰艱淵餘鑰鹽餘 (網蓋鏇鑰積網顧淵蓋鏇 )
积极
2024-05-13
临床3期
316
繭願願鑰願艱衊選鑰遞(膚範衊醖醖構蓋糧襯蓋) = 簾獵淵鹹鹹觸繭繭艱廠 願淵淵窪選顧餘獵願壓 (積鹹鑰艱窪糧範艱齋鹹 )
积极
2023-12-04
临床3期
250
觸膚廠夢鏇鬱觸餘觸鑰(網積製鏇觸襯醖窪蓋觸) = VLA1553 administered as a single-dose was generally well tolerated in adolescents aged 12 to <18 years, irrespective of previous CHIKV infection and showed a similar safety profile as reported in adults 壓艱繭壓鹹網願蓋夢窪 (憲鏇製製淵選鹽餘鹽築 )
积极
2023-11-23
NCT04546724 (FDA)
人工标引Manual
临床3期
4,115
淵構鑰範艱簾範選艱餘(齋觸選壓製窪廠夢衊淵) = 積餘鹹觸淵築膚選壓鑰 選廠積壓製襯獵糧廠夢 (鬱築糧選鏇憲壓遞廠淵, 96.7 ~ 99.8)
积极
2023-11-09
Placebo
淵構鑰範艱簾範選艱餘(齋觸選壓製窪廠夢衊淵) = 願鬱鹹願製鏇齋夢衊鹽 選廠積壓製襯獵糧廠夢 (鬱築糧選鏇憲壓遞廠淵, 0.0 ~ 3.8)
临床3期
409
鹹齋齋積鬱範願夢襯淵(壓醖餘積蓋壓蓋築鑰鬱) = 構鬱範膚繭醖齋廠鑰餘 鹽築簾構衊醖壓繭糧鏇 (鹹憲廠顧鹹廠蓋願構餘, 襯網窪醖廠淵築淵鹽膚 ~ 鏇願餘壓鬱淵構顧範鑰)
-
2023-09-28
鹹齋齋積鬱範願夢襯淵(壓醖餘積蓋壓蓋築鑰鬱) = 構製築鏇窪鹽簾襯壓艱 鹽築簾構衊醖壓繭糧鏇 (鹹憲廠顧鹹廠蓋願構餘, 構壓憲壓鬱獵廠鏇觸簾 ~ 網襯窪窪衊襯鹽夢窪鏇)
临床3期
4,115
蓋願製夢蓋遞鹹製憲範(獵網鬱築糧積範醖簾鬱) = 獵築糧鑰顧構鑰觸簾衊 製壓膚衊選觸淵壓範鬱 (鹽簾憲顧構選製獵製製, 96.7 ~ 99.8)
积极
2022-10-13
Placebo
蓋願製夢蓋遞鹹製憲範(獵網鬱築糧積範醖簾鬱) = 艱衊觸醖糧鹹鏇繭廠憲 製壓膚衊選觸淵壓範鬱 (鹽簾憲顧構選製獵製製, 0.0 ~ 3.8)
登录后查看更多信息

转化医学

使用我们的转化医学数据加速您的研究。
使用我们的转化医学数据加速您的研究。

药物交易

使用我们的药物交易数据加速您的研究。
使用我们的药物交易数据加速您的研究。

核心专利

使用我们的核心专利数据促进您的研究。
使用我们的核心专利数据促进您的研究。

临床分析

紧跟全球注册中心的最新临床试验。
紧跟全球注册中心的最新临床试验。

批准

利用最新的监管批准信息加速您的研究。
利用最新的监管批准信息加速您的研究。

特殊审评

只需点击几下即可了解关键药物信息。
只需点击几下即可了解关键药物信息。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路,让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用